Cancer immunotherapy by combining the selective COX-2 inhibitor and type I IFN signaling

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K19071
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Human pathology
• Research Institution: Asahikawa Medical College
• Principal Investigator: KOSAKA Akemi 旭川医科大学, 医学部, 助教 (40561030)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: COX-2阻害薬 / STINGアゴニスト

Outline of Final Research Achievements

The aim for this study is to development of an efficient and convenient cancer immunotherapy and to elucidate the mechanism when combining the selective COX-2 inhibitor celecoxib and the type I IFN inducer 2’3’-cGAMP.We used different mouse tumor models to determine the treatment regimen of celecoxib and 2’3’-cGAMP. The combination therapy showed a significant antitumor effect on tumor growth in mice compared to control and monotherapy with celecoxib or 2’3’-cGAMP. The antitumor effect of the combination therapy was not dependent on CD8+ T-cells and macrophages, and it was suggested that the type I IFN signaling pathway may not be involved in the antitumor responses of the combination therapy.

Free Research Field

腫瘍免疫